152 related articles for article (PubMed ID: 34189749)
1. Talimogene laherparepvec pseudolymphomatous reaction mimicking metastatic melanoma.
Henning A; Agnese D; Chung CG
J Cutan Pathol; 2021 Nov; 48(11):1423-1426. PubMed ID: 34189749
[TBL] [Abstract][Full Text] [Related]
2. Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases.
Everett AS; Pavlidakey PG; Contreras CM; De Los Santos JF; Kim JY; McKee SB; Kaufman HL; Conry RM
J Cutan Pathol; 2018 Jan; 45(1):48-53. PubMed ID: 28940544
[TBL] [Abstract][Full Text] [Related]
3. Kaposi's varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab.
Miller DM; Trowbridge RM; Desai A; Drews RE
J Immunother Cancer; 2018 Nov; 6(1):122. PubMed ID: 30454071
[TBL] [Abstract][Full Text] [Related]
4. Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe.
Gutzmer R; Harrington KJ; Hoeller C; Lebbé C; Malvehy J; Öhrling K; Downey G; Dummer R
Eur J Dermatol; 2018 Dec; 28(6):736-749. PubMed ID: 30698145
[TBL] [Abstract][Full Text] [Related]
5. Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience.
Perez MC; Miura JT; Naqvi SMH; Kim Y; Holstein A; Lee D; Sarnaik AA; Zager JS
Ann Surg Oncol; 2018 Dec; 25(13):3960-3965. PubMed ID: 30298318
[TBL] [Abstract][Full Text] [Related]
6. Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience.
Louie RJ; Perez MC; Jajja MR; Sun J; Collichio F; Delman KA; Lowe M; Sarnaik AA; Zager JS; Ollila DW
J Am Coll Surg; 2019 Apr; 228(4):644-649. PubMed ID: 30690076
[TBL] [Abstract][Full Text] [Related]
7. Surgical Resection After Talimogene Laherparepvec for Melanoma: Persistent Fuorodeoxyglucose Avidity on Positron Emission Tomography Despite No Viable Disease.
MacArthur TA; Fahy AS; Jakub JW
Am Surg; 2021 Jun; 87(6):849-854. PubMed ID: 34060947
[TBL] [Abstract][Full Text] [Related]
8. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
Gangi A; Zager JS
Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
[TBL] [Abstract][Full Text] [Related]
9. Talimogene laherparepvec (T-VEC) in advanced melanoma: complete response in a heart and kidney transplant patient. A case report.
Ressler J; Silmbrod R; Stepan A; Tuchmann F; Cicha A; Uyanik-Ünal K; Hoeller C
Br J Dermatol; 2019 Jul; 181(1):186-189. PubMed ID: 30776080
[TBL] [Abstract][Full Text] [Related]
10. Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey.
Mohr P; Haferkamp S; Pinter A; Weishaupt C; Huber MA; Downey G; Öhrling K; Loquai C; Louie KS
Adv Ther; 2019 Jan; 36(1):101-117. PubMed ID: 30536143
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB/II trial.
Monga V; Miller BJ; Tanas M; Boukhar S; Allen B; Anderson C; Stephens L; Hartwig S; Varga S; Houtman J; Wang L; Zhang W; Jaber O; Thomason J; Kuehn D; Rajput M; Metz C; Zamba KD; Mott S; Abanonu C; Bhatia S; Milhem M
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330766
[TBL] [Abstract][Full Text] [Related]
12. The histological spectrum of talimogene laherparepvec (TVEC) injections-Neutrophilic and chronic granulomatous dermatitis.
Lee K; Pouldar D; Shiu J; Elsensohn A; de Feraudy S
J Cutan Pathol; 2019 Feb; 46(2):165-167. PubMed ID: 30414194
[No Abstract] [Full Text] [Related]
13. An evaluation of talimogene laherparepvec for the treatment of melanoma.
Broman KK; Zager JS
Expert Opin Biol Ther; 2020 Jan; 20(1):9-14. PubMed ID: 31690129
[No Abstract] [Full Text] [Related]
14. Review of talimogene laherparepvec: A first-in-class oncolytic viral treatment of advanced melanoma.
Haitz K; Khosravi H; Lin JY; Menge T; Nambudiri VE
J Am Acad Dermatol; 2020 Jul; 83(1):189-196. PubMed ID: 32004650
[TBL] [Abstract][Full Text] [Related]
15. Panniculitis in a patient with pathologic complete response to talimogene laherparepvec treatment for recurrent, in-transit melanoma.
Long TH; Shinohara MM; Argenyi ZB; Thompson JA; Gardner JM
J Cutan Pathol; 2018 Nov; 45(11):864-868. PubMed ID: 30054925
[TBL] [Abstract][Full Text] [Related]
16. Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors.
Chesney J; Imbert-Fernandez Y; Telang S; Baum M; Ranjan S; Fraig M; Batty N
Melanoma Res; 2018 Jun; 28(3):250-255. PubMed ID: 29561296
[TBL] [Abstract][Full Text] [Related]
17. Extensive Pigment Incontinence Mimicking Persistent Melanoma After Talimogene Laherparepvec Therapy.
Danesh M; Faulkner-Jones B; Desai A; Kim CC
JAMA Dermatol; 2019 Apr; 155(4):496-497. PubMed ID: 30758504
[No Abstract] [Full Text] [Related]
18. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.
Andtbacka RH; Agarwala SS; Ollila DW; Hallmeyer S; Milhem M; Amatruda T; Nemunaitis JJ; Harrington KJ; Chen L; Shilkrut M; Ross M; Kaufman HL
Head Neck; 2016 Dec; 38(12):1752-1758. PubMed ID: 27407058
[TBL] [Abstract][Full Text] [Related]
19. Complete response with talimogene laherparepvec in recurrent melanoma of the ear: A case report.
Hsu AC; Kokot NC; Eisenberg BL; Thomas JS
Oral Oncol; 2020 Dec; 111():104899. PubMed ID: 32665184
[TBL] [Abstract][Full Text] [Related]
20. How We Do It: Administration Guide for Intralesional Immunotherapy With Talimogene Laherparepvec (T-VEC) for Advanced Melanoma.
Queen D; Samie FH; Zeitouni NC
Dermatol Surg; 2020 Nov; 46(11):1455-1457. PubMed ID: 31403542
[No Abstract] [Full Text] [Related]
[Next] [New Search]
